OTCMKTS:BAYRY Bayer Aktiengesellschaft (BAYRY) Stock Price, News & Analysis $14.05 -0.14 (-0.95%) As of 01:30 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendEarningsNews and TrendsSEC FilingsShort Interest About Bayer Aktiengesellschaft Stock (OTCMKTS:BAYRY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BAYRY alerts:Sign Up Key Stats Today's Range$14.01▼$14.2350-Day Range$13.13▼$14.4452-Week Range$7.48▼$15.23Volume248,303 shsAverage Volume1.13 million shsMarket Capitalization$55.20 billionP/E RatioN/ADividend Yield0.14%Price TargetN/AConsensus RatingBuy Company Overview Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863, the company develops and markets products in healthcare and agriculture and serves customers in markets around the world. Bayer’s American depositary shares trade over the counter under the symbol BAYRY. The company operates through three principal areas: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals business develops prescription medicines in areas such as cardiovascular disease, women’s health, oncology, neurology and specialty therapeutics. Consumer Health offers nonprescription products, including brands in pain relief, allergy care, dermatology, nutritional supplements and digestive health. Crop Science supplies seeds, crop-protection products and digital tools designed to support farmers and improve agricultural productivity. Bayer has expanded its operations internationally through internal research and development, partnerships and acquisitions, including the acquisition of Monsanto in 2018, which strengthened its seeds and agricultural technology business. Bill Anderson has served as Bayer’s chief executive officer since June 2023 and also leads the company’s ongoing organizational transformation.AI Generated. May Contain Errors. Read More Bayer Aktiengesellschaft Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreBAYRY MarketRank™: Bayer Aktiengesellschaft scored higher than 45% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingBuy Consensus RatingBayer Aktiengesellschaft has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 2 strong buy ratings, 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBayer Aktiengesellschaft has only been the subject of 2 research reports in the past 90 days.Read more about Bayer Aktiengesellschaft's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings Growth4.69% Earnings GrowthEarnings for Bayer Aktiengesellschaft are expected to grow by 4.69% in the coming year, from $1.28 to $1.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bayer Aktiengesellschaft is -27.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bayer Aktiengesellschaft is -27.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioBayer Aktiengesellschaft has a PEG Ratio of 2.11. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBayer Aktiengesellschaft has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Bayer Aktiengesellschaft's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Bayer Aktiengesellschaft has been sold short.Short Interest Ratio / Days to CoverBayer Aktiengesellschaft has a short interest ratio ("days to cover") of 0.18, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bayer Aktiengesellschaft has recently decreased by 80.77%, indicating that investor sentiment is improving significantly. Dividend0.8 / 5Dividend StrengthWeak Dividend YieldBayer Aktiengesellschaft has a dividend yield of 0.17%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthBayer Aktiengesellschaft does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Bayer Aktiengesellschaft will have a dividend payout ratio of 1.49% next year. This indicates that Bayer Aktiengesellschaft will be able to sustain or increase its dividend.Read more about Bayer Aktiengesellschaft's dividend. News and Social Media2.1 / 5News Sentiment0.28 News SentimentBayer Aktiengesellschaft has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Bayer Aktiengesellschaft this week, compared to 5 articles on an average week.Search Interest10 people have searched for BAYRY on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Bayer Aktiengesellschaft to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bayer Aktiengesellschaft insiders have not sold or bought any company stock.Percentage Held by InstitutionsBayer Aktiengesellschaft has minimal institutional ownership at this time.Read more about Bayer Aktiengesellschaft's insider trading history. Receive BAYRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bayer Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BAYRY Stock News HeadlinesBayer’s Hemophilia A Gene Therapy Trial Reaches Completion, Signaling Next Steps for BAYRY1 hour ago | tipranks.comGrünenthal GmbH agreed to acquire Stivarga from Bayer Aktiengesellschaft.September 21 at 10:27 PM | marketscreener.comMThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.September 23 at 1:00 AM | Banyan Hill Publishing (Ad)Bayer Sells Cancer Drug to Gruenenthal for Up to $431 MillionSeptember 21 at 8:23 AM | wsj.comBayer Aktiengesellschaft (OTCMKTS:BAYRY) Stock Crosses Below 50 Day Moving Average - Time to Sell?September 19, 2026 | americanbankingnews.comBayer's KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 DiabetesSeptember 17, 2026 | businesswire.comBayer's Monsanto unit urges Missouri judge to approve $7.25 billion Roundup settlementSeptember 14, 2026 | reuters.comBayer faces pivotal test of $7.25 billion Roundup settlement in Missouri courtSeptember 11, 2026 | reuters.comSee More Headlines BAYRY Stock Analysis - Frequently Asked Questions How have BAYRY shares performed this year? Bayer Aktiengesellschaft's stock was trading at $10.82 at the beginning of 2026. Since then, BAYRY shares have increased by 31.5% and is now trading at $14.23. How were Bayer Aktiengesellschaft's earnings last quarter? Bayer Aktiengesellschaft (OTCMKTS:BAYRY) posted its earnings results on Tuesday, August, 4th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.23 by $0.06. The business had revenue of $12.53 billion for the quarter, compared to the consensus estimate of $12.31 billion. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive trailing twelve-month return on equity of 16.77%. Does Bayer Aktiengesellschaft have any subsidiaries? Bayer Aktiengesellschaft subsidiaries include these companies: Asklepios BioPharmaceutical, Care/of, KaNDy Therapeutics, BlueRock Therapeutics, Monsanto Company, Zoner.ag, Dihon Pharmaceutical, and others. How do I buy shares of Bayer Aktiengesellschaft? Shares of BAYRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/04/2026Today9/23/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:BAYRY CIK1144145 Webwww.bayer.com Phone49214301Fax49-21-4306-6328Employees88,078Year Founded1863Profitability EPS (Trailing Twelve Months)($0.51) Trailing P/E RatioN/A Forward P/E Ratio11.00 P/E Growth2.11Net Income-$4.10 billion Net Margins-3.80% Pretax Margin-2.10% Return on Equity16.77% Return on Assets4.53% Debt Debt-to-Equity Ratio1.05 Current Ratio1.04 Quick Ratio0.67 Sales & Book Value Annual Sales$51.55 billion Price / Sales1.07 Cash Flow$2.19 per share Price / Cash Flow6.43 Book Value$7.50 per share Price / Book1.88Miscellaneous Outstanding Shares3,930,000,000Free FloatN/AMarket Cap$55.31 billion OptionableNot Optionable Beta0.56 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:BAYRY) was last updated on 9/23/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bayer Aktiengesellschaft Please log in to your account or sign up in order to add this asset to your watchlist. Share Bayer Aktiengesellschaft With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
